Sponsors
The bill aims to speed and clarify FDA GRAS/E review for OTC monograph drugs—improving predictability and consumer access—but risks lowering evidence standards, shifting FDA resources, and favoring larger manufacturers over smaller firms.
Patients and consumers could gain faster access to safe OTC treatments because clearer and less-burdensome GRAS/E guidance can accelerate FDA decisions and market entry.
Manufacturers — particularly those seeking approvals — will face clearer, more predictable regulatory expectations, reducing uncertainty and potentially speeding commercialization.
Requestors receive documented feedback (meeting minutes and written study-parameter recommendations), improving transparency and predictability of FDA review interactions.
Taxpayers and consumers could face higher safety risks if the 'least burdensome' standard leads to acceptance of weaker or insufficient evidence of safety/effectiveness.
Streamlining regulatory interactions could advantage larger manufacturers with regulatory capacity and disadvantage smaller firms that lack resources to engage in study-design discussions.
New procedural obligations for FDA to hold meetings and document recommendations may increase agency workload and divert resources from other reviews and public-health priorities.
Based on analysis of 2 sections of legislative text.
Directs FDA to use the least burdensome review for certain OTC GRAS/E requests and to meet with requestors, provide written study recommendations, and include meeting summaries in the record.
Introduced December 18, 2025 by Greg Landsman · Last progress December 18, 2025
Creates a new procedural requirement for FDA reviews of requests to classify over-the-counter (OTC) monograph drugs as "generally recognized as safe and effective" (GRAS/E). It directs the agency to use the least burdensome appropriate means, to meet with requestors who ask for a written meeting, to provide written recommendations on necessary evidence (including study design/size), and to include meeting summaries and recommendations in the administrative record. Another short section simply designates a short title for the Act.